Please login to the form below

Not currently logged in
Email:
Password:

FDA warns about birth control pills

The US Food and Drug Administration has issued a safety review following links between birth control pills containing drospirenone and an increase in blood clots

The US Food and Drug Administration (FDA) has ordered a safety review following links between birth control pills containing drospirenone and an increase in blood clots.

Brand names affected by the review include Beyaz, Safyral, Yasmin and Yaz [all Bayer]; Gianvi [Teva], Zarah [Watson] and Loryna [Sandoz].  The FDA has a full list of affected drugs.

The FDA said: "All birth control pills pose a risk of blood clots. Several epidemiological studies have reported that the risk of blood clots for women who use birth control pills containing drospirenone is higher than that for women who use birth control pills containing the progestin levonorgestrel."

Drospirenone is a type of female sex hormone called a progestin, which works by preventing ovulation in a woman.

The FDA cited two recent studies that demonstrated a greater risk of blood clots for women taking birth control pills containing drospirenone compared to the risk in women taking birth control pills containing levonorgestrel - another progestin.

Previous studies that indicated no difference in the risk of blood clots between the two types of drugs were also noted by the agency.

The FDA said it is evaluating the conflicting results from the studies, and is analysing all currently available information to determine the risks and benefits of drospirenone-containing birth control pills.

The warning follows an announcement by the European Medicines Agency (EMA) in May 2011 that it is to update product information on oral contraceptives containing drospirenone and ethinyl estradiol regarding the risk of venous thromboembolism based on information from the same reports under analysis by the FDA.

1st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics